COUMPOUNDS AND METHODS FOR INHIBITING THE INTERACTION OF BCL PROTEINS WITH BINDING PARTNERS
World Intellectual Property Organization Patent
Stats

Importance
| WO Family Size
|
Non-US Coverage
|
Abstract
One aspect of the present invention relates to isoxazoline derivatives that bind to bcl proteins and inhibit Bcl function. Another aspect of the present invention relates to compositions comprising an isoxazoline derivative of the invention. The present invention provides methods for treating and modulating disorders associated with hyperproliferation, such as cancer.
First Claim
Family
- 15 United States
- 10 France
- 8 Japan
- 7 China
- 5 Korea
- 2 Other
Country Designations
Patent Owner(s)
| Patent Owner | Address |
|---|---|
| INFINITY PHARMACEUTICALS INC | USCAMBRIDGE MA 02139 |
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Inventor(s)
| Inventor Name | Address |
|---|---|
| CASTRO ALFREDO C | SOMERVILLE MA |
| FOLEY MICHAEL A | NEW YORK NY |
| YU LIN-CHEN | QUINCY MA |
| GROGAN MICHAEL J | WINCHESTER MA |
| LIU TAO | U S A |
| MANN DAVID A | SARASOTA FL |
| UNDERWOOD DENNIS J | JAMAICA PLAIN MA |
| DENG WEI | SAN DIEGO CA |
| GEORGES EVANGELINOS ASIMINA T | MASSACHUSETTS MASSACHUSETTS |
| DEPEW KRISTOPHER M | ACTON MA |
| FRITZ CHRISTIAN C | NATICK MA 01760 |
| HAFEEZ NAFEEZA | CAMBRIDGE MASSACHUSETTS 02139 |
| HOLSON EDWARD B | NEWTON HIGHLANDS MA |
| KONEY NII O | NEW YORK NY |
| HOPKINS BRIAN T | CAMBRIDGE MA 02142 |
| WYLIE ANDREW A | BROOKLINE MA 02446 |
| SNYDER DANIEL A | MANCHESTER CT CONNECTICUT 06040 |
| MARCAURELLE LISA A | ARLINGTON MA |
| ZHANG LINPING | LEXINGTON MA |
Cited Art Landscape
- No Cited Art to Display
Full Text
Legal Events
Matter Detail
Update Public Data
Dismiss
Edit
Save
Renewals Detail
Edit
Save
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Note
The template below is formatted to ensure compatibility with our system.
Provide tags with | separated like (tags1|tags2).
Maximum length is 128 characters for Customer Application No
Mandatory Fields * - 'MatterType','AppType','Country','Title','SerialNo'.
Acceptable Date Format - 'MM/DD/YYYY'.
Acceptable Filing/App Types -
- Continuation/Divisional
- Original
- Paris Convention
- PCT National
- With Priority
- EP Validation
- Provisional Conversion
- Reissue
- Provisional
- Foreign Extension
Acceptable Status -
- Pending
- Abandoned
- Unfiled
- Expired
- Granted
Acceptable Matter Types -
- Patent
- Utility Model
- Supplemental Protection Certificate
- Design
- Inventor Certificate
- Plant
- Statutory Invention Reg
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Success
E-mail has been sent successfully.
Failure
Some error occured while sending email. Please check e-mail and try again!
Important Notes on Latency of Status data
This Status indicator is an estimation based on the relevant document kind code. As such, it status will only indicate "Published" or "Granted". Expired, lapsed or abandoned statuses are not available in this release. Please refer to the legal status information for more information.
This status should not be taken as legal conclusion. No representations are made as to the accuracy of the status provided. Please consult a legal professional before relying on this status information.
Important Note on Priority Date data
This priority date is an estimated earliest priority date and is purely an estimation. This date should not be taken as legal conclusion. No representations are made as to the accuracy of the date listed. Please consult a legal professional before relying on this date.
Only for Granted EP cases
EP validations represent the countries in which the EP patent may be in force. Data is based on reporting from the various EP contracting states. The reporting consistency can vary across the countries.